"Big earthquake" with volume purchasing, the retail pattern of generic pharmaceutical enterprises will be reshaped

Following the "9 / 11" in the pharmaceutical industry, pharmaceutical stocks fell sharply in a row People from all walks of life discussed the impact of volume purchasing on the entire pharmaceutical industry and its own enterprises The quantity of boots purchased has not been implemented yet, and the consistency evaluation pharmaceutical enterprises take this opportunity to quickly increase their efforts Hengrui, Fosun, Xiansheng pharmaceutical and Kangenbei have passed the consistency evaluation of irbesartan tablets, Azithromycin Capsules, risuvastatin calcium tablets and Amoxicillin Capsules, respectively, in order to further seize the market share of 20% - 30% of the country Although pharmaceutical companies are racing to speed up the progress of consistency evaluation, the official announcement of on volume procurement is always on the way On August 28, 2018, the State Council issued the key tasks of medical reform in the second half of the year, which made it clear that the national drug centralized procurement pilot will be carried out to significantly reduce drug prices At present, Shanghai has carried out the third batch of drug volume procurement, and Wuhan announced on October 17 that it will carry out the first batch of drug volume procurement, involving 48 varieties With the tail of 2018 coming quietly, volume purchasing is bound to be one of the most important plays in the pharmaceutical industry in the second half of the year What will be the impact on the enterprises in various segments of the pharmaceutical industry? Top 3 in the field of volume procurement variety treatment includes 33 consistency evaluation varieties selected under the common name according to the first batch of volume procurement list published by the National Medical Security Bureau at the pilot joint procurement Symposium According to the MI Nei net database, 10 of 33 varieties are cardiovascular system drugs, 7 are nervous system drugs, 7 are systemic anti infective drugs, 4 are anti-tumor and immunomodulators, 2 are digestive system and metabolic drugs, and 1 is blood and hematopoietic system drugs, respiratory system drugs and muscle bone system drugs It is a good market development opportunity for enterprises that have long been deeply engaged in the fields of cardiovascular, neurological, anti infection or product therapy, and related products have passed the consistency evaluation As the big winner of the first batch of volume purchase, 7 of the 10 drugs that have passed the consistency evaluation of Huahai pharmaceutical industry are in the pilot purchase list, among which 5 drugs belong to cardiovascular system drugs and 2 drugs belong to nervous system drugs Two of the four drugs of Zhengda Tianqing belong to cardiovascular system drugs and systemic anti infective drugs There are two, one and one in cardiovascular system drugs, one in nervous system drugs, one in digestive system drugs and one in metabolic drugs Among them, Fosun Pharmaceutical and Shiyao group are the most abundant in the field of product therapy Four drugs that passed the consistency evaluation of Fosun medicine are all in the purchase list, and they are respectively cardiovascular system drugs, nervous system drugs, systemic anti infective drugs, digestive system and metabolic drugs Shiyao group's four over consistent evaluation volume purchased drugs are respectively cardiovascular system drugs, nervous system drugs, systemic anti infective drugs, anti-tumor drugs and immunomodulators In the field of national procurement of varieties and treatment and through the consistency evaluation of manufacturers' procurement of "one leaf knows the autumn", 2018 is the big limit of the consistency evaluation of "289" varieties With the introduction of the good policy of the provinces' consistent evaluation, the companies of generic drugs carry out the consistency evaluation continuously However, with the sound of thunder in Pingdi, the Symposium on volume purchase of the medical insurance bureau was held, taking the consistency evaluation of enterprise drugs as the ticket for volume purchase, and jointly competing with the original research manufacturers for 20% - 30% of the market share of the country So far, the importance of consistency evaluation for generic pharmaceutical enterprises is self-evident Many enterprises have expressed that they will accelerate the progress of consistency evaluation Fosun Pharma, which holds 4 over consistency evaluation drugs purchased with quantity, said that the policy of purchasing with quantity is conducive to introducing products with high quality and high price into the market The company will make full use of this opportunity, strive to ensure and expand the market position of advantageous varieties, and rearrange the market opportunities of products In 2018, Fosun Group will select more than 50 varieties in the fields of cardiovascular system, metabolism and digestive system, central nervous system, anti infection and other disease treatment to carry out consistency evaluation, and relevant work is in progress in an orderly manner According to minenet data, atorvastatin calcium tablets in new Donggang accounted for 2.56% of the end market of public medical institutions in 2017 In this regard, Lepu medical believes that national volume procurement is an important opportunity for the company, which is "a significant positive for the recent growth of atorvastatin products" If the company wins the bid successfully, it will make a great contribution to the company's performance, and its profit will increase several times If it goes well, clopidogrel sulfate should be approved within 1-2 months; other varieties are in different stages of consistency evaluation and will be completed in succession In addition, the recognized profit of Lepu in the pharmaceutical market is calculated based on the distribution price Therefore, the reduction of terminal price in the drug market caused by volume purchase does not affect the profit ratio of Lepu basically In recent two years, dextromethomidine and risperidone, which are newly listed by Enhua pharmaceutical, have been included in the scope of this volume purchase According to the intranet database, the terminal sales of dextromethomidine injection in China's public medical institutions in 2017 were 2.409 billion yuan, with Enhua pharmaceutical accounting for 6.66%; the terminal sales of risperidone tablets in China's public medical institutions in 2017 were 1.168 billion yuan, with Enhua pharmaceutical accounting for 12.85% In the near future, Enhua pharmaceutical will immediately start the application for conformity assessment On September 17, 2018, the application for conformity assessment of risperidone tablets of Enhua pharmaceutical was undertaken by CDE and entered the review and approval status It is understood that the main marketing products of Enhua Pharmaceutical Co., Ltd are concentrated in the central nervous system, and the marketing channels are all in the hospital In terms of the transformation of the company's marketing model brought by volume procurement, Enhua pharmaceutical believes that volume procurement does have a certain impact on the company's marketing model But the importance of marketing in the fields of anesthesia, severe illness and spirit will not be replaced, but will be strengthened Jingfeng pharmaceutical, whose products have not been listed in the first batch of volume purchase list, said that it will not have a significant impact on the company's production and operation for the time being At present, the company's consistency evaluation project has completed the preliminary preparation If it makes expected progress, it will be able to play an advantage in the volume bidding procurement, improve the company's product competitiveness and add new profit growth points Hainan Haiyao said that the company already has the production technology and capacity of the whole industrial chain from intermediates to APIs to chemicals in terms of chemicals At present, the company is fully promoting the consistency evaluation of key products Xiao Hanqing, general manager of Fangsheng pharmaceutical, said that the company will promote the consistency evaluation process, and strive to win the policy and market opportunities by 2-3 varieties passing the consistency evaluation next year Voice of these listed companies: limited impact of volume procurement from the current policy and analysis, the main impact of volume procurement is generic pharmaceutical enterprises, but for proprietary drugs, patent drugs, and pharmaceutical enterprises with exclusive varieties, there is no substantive impact Hainan Haiyao, Puluo pharmaceutical and other companies said that in the long run, the volume procurement will promote the industry to return to the sound development track of product quality, technology, market competitiveness, etc., which will play a positive role in the integration of API preparation enterprises Peking University Pharmaceutical said that the volume purchase policy is the catalyst for the future more centralized pharmaceutical industry and accelerated survival of the fittest These policies are conducive to unswervingly promoting the consistency evaluation of R & D work of pharmaceutical enterprises, and to the listed companies with strong background and R & D strength of the group China Resources said that the company's generic pharmaceutical business accounted for a relatively small proportion with limited impact Guangyuyuan said that the company focuses on the production and sales of traditional Chinese medicine, there is no generic medicine, and the market share of core varieties of OTC is relatively high, and the national drug volume procurement will not have a significant impact on the company's production and operation Qianhong pharmaceutical, Yiling pharmaceutical, sunflower pharmaceutical and other companies all said that as the company mainly uses patented Chinese patent medicine products, it is basically not affected by the volume purchase policy Guilin Sanjin, poinsettia and other companies said that the company's main products are all exclusive varieties, and it is expected that volume procurement will have limited impact on the company Zixin pharmaceutical said that in terms of prescription drug sales, for many years, the company's main varieties are mostly exclusive and two document varieties, so the impact is small Huadong pharmaceutical, Haite biology, Jiangsu Wuzhong and other companies said that the company's main products were not included in the first batch of volume procurement, with limited impact Dyne pharmaceutical said that the existing products mainly involve children's medicine, food and supplies and other children's treatment and health care fields, and the volume procurement has little impact on the company's varieties at present The volume purchase led to the outflow of prescriptions, which affected the pharmaceutical retail pattern Although the volume purchase mainly involved in the three links of pharmaceutical enterprises, distribution and hospitals in the industry, it seemed not to have much relationship with chain drugstore enterprises, but some pharmaceutical retail enterprises said that the volume purchase "takes one lead and moves the whole body", which also affected the change of pharmaceutical retail pattern Wang Fuguo, Secretary of the board of directors of Yifeng pharmacy, said that medical insurance fee control is an inevitable trend of China's medical security in the future, and volume sales is one of the measures taken by the country to achieve this goal, "in fact, chain drugstores have been implementing volume sales" He believes that drug distribution channels may be reshuffled due to the policy "In the short term, the price transmission mechanism caused by volume sales will reduce the gross profit margin of the same variety of products as the winning drugs for chain drugstores; in the long term, the winning enterprises are a few after all, and more pharmaceutical enterprises that lose market share of the hospital will incline their marketing policies to the channel of chain drugstores." In addition, Wang Fuguo believes that this policy is beneficial to the "prescription outflow" that the state has been promoting He analyzed that the volume sales let the hospital directly purchase from pharmaceutical companies, objectively cutting off the relationship between doctors and enterprises When there is no interest link, doctors will prefer professional and brand cognition to income orientation The drugstores near the public hospitals will take advantage of their location in the layout planning of chain drugstores because of the outflow of prescriptions after taking on volume sales Yixintang believes that volume purchase mainly involves the bidding behavior of public hospitals, and has little relevance to the pharmacy industry At present, it is expected that the price of generic drugs will drop after the original drugs pass the consistency evaluation At present, the main purpose of DTP pharmacy in the retail industry is to attract customers, and the gross profit of many drugs is not high Therefore, the transmission mechanism of the impact of volume purchase on drugstores needs to be further observed, but the preliminary judgment is that the impact on the chain drugstore industry is not great Zhang Yu, a secretary of the people's Congress, believes that volume procurement will bring alternative space for pharmaceutical retail, but he believes that the current policy promotion is not enough to fundamentally change the pattern of pharmaceutical retail industry, because of the difference in the payment capacity of medical insurance at all levels and regions, and the nationwide implementation of volume procurement still needs to be vigorously promoted In addition, as the volume procurement can not cover all varieties at present, the size of alternative space for chain drugstores in this area still needs to be considered Conclusion as the trend of the development of medical recruitment and purchase policy in the future, the volume purchase, on the basis of ensuring the quality, standardizes the price and uses the limited medical insurance fund to create the maximum effect for patients Its implementation is in line with the consistency evaluation policy, and the market share of the winning enterprises will be rapidly increased, the enthusiasm of enterprises to participate in the consistency evaluation will be improved, the pharmaceutical enterprises with weak competitiveness will be eliminated, and the industry will be led back to the original intention of R & D innovation At the same time, the volume purchase mode will promote the industry to change the existing sales mode, reduce the huge sales costs of enterprises, and trigger the outflow of prescriptions